Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line

C. G. Frondoza, S. M. Trivedi, Richard L Humphrey

Research output: Contribution to journalArticle

Abstract

Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg. With repeated transfer of LPC-1 cells followed by subcurative CY therapy, we have developed from this CY-sensitive parent line (CY-S) a stable CY-resistant subline (CY-R) that is unaffected by doses as large as 250 mg/kg. Stability of this induced CY resistance in the absence of CY treatment has been demonstrated for > 14 transfer generations. The CY-R subline has been compared to the CY-S parent line and shown to be similar with respect to morphology, growth kinetics, survival time, synthesis of IgG 2ak M component, and DNA content and distribution. The CY-S parent line responds in vivo to CY analogs (ifosfamide and trofosfamide), as judged by decreased tumor mass and increased survival; the CY-R subline is resistant to the CY analogs. The response to carmustine (BCNU) was tested, and resistance to CY did not predict for response to this alkylating agent since the effect on both CY-S and CY-R lines was equal. The significance of the development of this CY-resistant subline and the implications for future research into the mechanisms of such resistance are discussed.

Original languageEnglish (US)
Pages (from-to)1535-1544
Number of pages10
JournalCancer Treatment Reports
Volume66
Issue number7
StatePublished - 1982

Fingerprint

Plasmacytoma
Cyclophosphamide
Cell Line
Carmustine
Myeloma Proteins
Ifosfamide
Alkylating Agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frondoza, C. G., Trivedi, S. M., & Humphrey, R. L. (1982). Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. Cancer Treatment Reports, 66(7), 1535-1544.

Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. / Frondoza, C. G.; Trivedi, S. M.; Humphrey, Richard L.

In: Cancer Treatment Reports, Vol. 66, No. 7, 1982, p. 1535-1544.

Research output: Contribution to journalArticle

Frondoza, CG, Trivedi, SM & Humphrey, RL 1982, 'Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line', Cancer Treatment Reports, vol. 66, no. 7, pp. 1535-1544.
Frondoza, C. G. ; Trivedi, S. M. ; Humphrey, Richard L. / Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 7. pp. 1535-1544.
@article{c03d1c7ec4bb46609b22ea55a3749a47,
title = "Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line",
abstract = "Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg. With repeated transfer of LPC-1 cells followed by subcurative CY therapy, we have developed from this CY-sensitive parent line (CY-S) a stable CY-resistant subline (CY-R) that is unaffected by doses as large as 250 mg/kg. Stability of this induced CY resistance in the absence of CY treatment has been demonstrated for > 14 transfer generations. The CY-R subline has been compared to the CY-S parent line and shown to be similar with respect to morphology, growth kinetics, survival time, synthesis of IgG 2ak M component, and DNA content and distribution. The CY-S parent line responds in vivo to CY analogs (ifosfamide and trofosfamide), as judged by decreased tumor mass and increased survival; the CY-R subline is resistant to the CY analogs. The response to carmustine (BCNU) was tested, and resistance to CY did not predict for response to this alkylating agent since the effect on both CY-S and CY-R lines was equal. The significance of the development of this CY-resistant subline and the implications for future research into the mechanisms of such resistance are discussed.",
author = "Frondoza, {C. G.} and Trivedi, {S. M.} and Humphrey, {Richard L}",
year = "1982",
language = "English (US)",
volume = "66",
pages = "1535--1544",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line

AU - Frondoza, C. G.

AU - Trivedi, S. M.

AU - Humphrey, Richard L

PY - 1982

Y1 - 1982

N2 - Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg. With repeated transfer of LPC-1 cells followed by subcurative CY therapy, we have developed from this CY-sensitive parent line (CY-S) a stable CY-resistant subline (CY-R) that is unaffected by doses as large as 250 mg/kg. Stability of this induced CY resistance in the absence of CY treatment has been demonstrated for > 14 transfer generations. The CY-R subline has been compared to the CY-S parent line and shown to be similar with respect to morphology, growth kinetics, survival time, synthesis of IgG 2ak M component, and DNA content and distribution. The CY-S parent line responds in vivo to CY analogs (ifosfamide and trofosfamide), as judged by decreased tumor mass and increased survival; the CY-R subline is resistant to the CY analogs. The response to carmustine (BCNU) was tested, and resistance to CY did not predict for response to this alkylating agent since the effect on both CY-S and CY-R lines was equal. The significance of the development of this CY-resistant subline and the implications for future research into the mechanisms of such resistance are discussed.

AB - Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg. With repeated transfer of LPC-1 cells followed by subcurative CY therapy, we have developed from this CY-sensitive parent line (CY-S) a stable CY-resistant subline (CY-R) that is unaffected by doses as large as 250 mg/kg. Stability of this induced CY resistance in the absence of CY treatment has been demonstrated for > 14 transfer generations. The CY-R subline has been compared to the CY-S parent line and shown to be similar with respect to morphology, growth kinetics, survival time, synthesis of IgG 2ak M component, and DNA content and distribution. The CY-S parent line responds in vivo to CY analogs (ifosfamide and trofosfamide), as judged by decreased tumor mass and increased survival; the CY-R subline is resistant to the CY analogs. The response to carmustine (BCNU) was tested, and resistance to CY did not predict for response to this alkylating agent since the effect on both CY-S and CY-R lines was equal. The significance of the development of this CY-resistant subline and the implications for future research into the mechanisms of such resistance are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0019973103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019973103&partnerID=8YFLogxK

M3 - Article

C2 - 7093969

AN - SCOPUS:0019973103

VL - 66

SP - 1535

EP - 1544

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -